Free Trial
→ The national debt just passed $39 trillion (From US Gold Bureau) (Ad)tc pixel Free SXTC Stock Alerts

China SXT Pharmaceuticals (SXTC) Competitors

China SXT Pharmaceuticals logo
$0.34 -2.49 (-87.99%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 +0.05 (+14.41%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SXTC vs. GELS, NCNA, PULM, LEXX, and GLMD

Should you buy China SXT Pharmaceuticals stock or one of its competitors? China SXT Pharmaceuticals's main competitors and comparable companies include Gelteq (GELS), NuCana (NCNA), Pulmatrix (PULM), Lexaria Bioscience (LEXX), and Galmed Pharmaceuticals (GLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does China SXT Pharmaceuticals compare to Gelteq?

Gelteq (NASDAQ:GELS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Gelteq has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Gelteq has higher earnings, but lower revenue than China SXT Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gelteq$110K54.53-$4.30MN/AN/A
China SXT Pharmaceuticals$1.14M1.19-$6.20MN/AN/A

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, China SXT Pharmaceuticals had 5 more articles in the media than Gelteq. MarketBeat recorded 5 mentions for China SXT Pharmaceuticals and 0 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Gelteq Neutral
China SXT Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gelteq
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
GelteqN/A N/A N/A
China SXT Pharmaceuticals N/A N/A N/A

Summary

China SXT Pharmaceuticals beats Gelteq on 5 of the 7 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to NuCana?

China SXT Pharmaceuticals (NASDAQ:SXTC) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

China SXT Pharmaceuticals' return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
NuCana N/A -41.90%-33.69%

China SXT Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, NuCana has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

China SXT Pharmaceuticals has higher revenue and earnings than NuCana.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.19-$6.20MN/AN/A
NuCanaN/AN/A-$38.71M-$3.81N/A

In the previous week, China SXT Pharmaceuticals had 5 more articles in the media than NuCana. MarketBeat recorded 5 mentions for China SXT Pharmaceuticals and 0 mentions for NuCana. NuCana's average media sentiment score of 0.32 beat China SXT Pharmaceuticals' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
NuCana Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

China SXT Pharmaceuticals beats NuCana on 5 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Pulmatrix?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

China SXT Pharmaceuticals' return on equity of 0.00% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Pulmatrix N/A -125.65%-95.19%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, China SXT Pharmaceuticals had 4 more articles in the media than Pulmatrix. MarketBeat recorded 5 mentions for China SXT Pharmaceuticals and 1 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.67 beat China SXT Pharmaceuticals' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
China SXT Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pulmatrix
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pulmatrix has higher revenue and earnings than China SXT Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.19-$6.20MN/AN/A
Pulmatrix$7.81M0.70-$5.16M-$1.10N/A

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

China SXT Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Summary

China SXT Pharmaceuticals and Pulmatrix tied by winning 5 of the 10 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Lexaria Bioscience?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, China SXT Pharmaceuticals had 5 more articles in the media than Lexaria Bioscience. MarketBeat recorded 5 mentions for China SXT Pharmaceuticals and 0 mentions for Lexaria Bioscience. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
Lexaria Bioscience Neutral

China SXT Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

China SXT Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.19-$6.20MN/AN/A
Lexaria Bioscience$710K10.28-$11.90M-$5.10N/A

China SXT Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Lexaria Bioscience N/A -174.93%-143.89%

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 550.29%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lexaria Bioscience
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

China SXT Pharmaceuticals and Lexaria Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

China SXT Pharmaceuticals has higher revenue and earnings than Galmed Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed PharmaceuticalsN/AN/A-$10.31M-$15.18N/A
China SXT Pharmaceuticals$1.14M1.19-$6.20MN/AN/A

China SXT Pharmaceuticals' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Galmed PharmaceuticalsN/A -73.68% -60.88%
China SXT Pharmaceuticals N/A N/A N/A

Galmed Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, China SXT Pharmaceuticals had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 5 mentions for China SXT Pharmaceuticals and 0 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat China SXT Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Galmed Pharmaceuticals Positive
China SXT Pharmaceuticals Neutral

Summary

China SXT Pharmaceuticals beats Galmed Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTC vs. The Competition

Export
MetricChina SXT PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$163K$12.25B$7.14B$13.21B
Dividend YieldN/A2.65%2.53%16.47%
P/E RatioN/A802.39275.1525.94
Price / Sales0.14747.53566.7983.59
Price / CashN/A86.0477.4152.81
Price / Book0.0010.6610.806.27
Net Income-$6.20M$2.83B$3.50B$382.13M
7 Day Performance-88.51%-1.62%-2.02%-1.35%
1 Month Performance-84.82%-7.65%-7.53%-5.60%
1 Year Performance-100.00%-6.26%3.32%-1.54%

China SXT Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTC
China SXT Pharmaceuticals
0.2386 of 5 stars		$0.34
-88.0%		N/A-100.0%$163K$1.14MN/A56
GELS
Gelteq
N/A$0.53
-0.2%		N/A-54.8%$5.68M$165.65KN/A8
NCNA
NuCana
0.8376 of 5 stars		$1.35
+11.6%		N/A-83.8%$5.62MN/AN/A11
PULM
Pulmatrix
0.6891 of 5 stars		$1.52
-2.4%		N/A-68.0%$5.55M$7.81MN/A2
LEXX
Lexaria Bioscience
1.2691 of 5 stars		$3.15
+0.6%		$22.50
+614.3%		-72.4%$5.21M$194KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 10/8/2026 by MarketBeat.com Staff.
From Our Partners
A dividend every week of the year
Most dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...
Market Savvy | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
"The largest market in human history"
SpaceX quietly filed paperwork describing what it calls the largest actionable total addressable market in hum...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel